HWAM
BBIO icon

Hennion & Walsh Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Hennion & Walsh Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,484
Closed -$1.58M – 934
2025
Q3 		$1.58M Sell
30,484
-5,685
-16% -$277K 0.06% 397
2025
Q2 		$1.56M Sell
36,169
-540
-1% -$19.6K 0.06% 367
2025
Q1 		$1.27M Sell
36,709
-950
-3% -$32K 0.06% 414
2024
Q4 		$1.03M Sell
37,659
-384
-1% -$9.92K 0.05% 462
2024
Q3 		$969K Sell
38,043
-1,056
-3% -$27.7K 0.05% 455
2024
Q2 		$990K Sell
39,099
-104,995
-73% -$2.87M 0.05% 422
2024
Q1 		$4.46M Buy
144,094
+22,441
+18% +$763K 0.24% 95
2023
Q4 		$4.91M Buy
121,653
+33,672
+38% +$1.01M 0.28% 74
2023
Q3 		$2.32M Buy
87,981
+3,494
+4% +$99.2K 0.15% 185
2023
Q2 		$1.45M Sell
84,487
-2,276
-3% -$34.2K 0.09% 286
2023
Q1 		$1.44M Sell
86,763
-2,742
-3% -$32K 0.09% 277
2022
Q4 		$682K Buy
89,505
+11,152
+14% +$107K 0.04% 423
2022
Q3 		$779K Buy
78,353
+19,508
+33% +$203K 0.05% 386
2022
Q2 		$534K Buy
+58,845
New +$492K 0.03% 468

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hennion & Walsh Asset Management's BBIO Position: Q4 2025 in Review

Hennion & Walsh Asset Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 30,484 shares — an estimated $1.58M sold.

Hennion & Walsh Asset Management first reported a position in BBIO in Q2 2022 and held it in 14 quarters. The position peaked at $4.91M in Q4 2023. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Hennion & Walsh Asset Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 30,484 BridgeBio Pharma shares in Q4 2025, an estimated $1.58M.
  • Hennion & Walsh Asset Management first reported a position in BridgeBio Pharma in Q2 2022 and held it in 14 quarters.
  • Hennion & Walsh Asset Management's BridgeBio Pharma position peaked at $4.91M in Q4 2023.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2025, filed 14 Jan 2026.